| | Cardiovascular Diabetology | Full text | The need for a large-scale trial of fibrate therapy in diabetes: the rationale ... (Site not responding. Last check: 2007-10-22) |
 | | Fibrates correct the typical lipid abnormalities of type 2 diabetes mellitus, yet no study, to date, has specifically set out to evaluate the role of fibrate therapy in preventing cardiovascular events in this setting. |
 | | As fibrates are known to correct the typical dyslipidaemia of diabetes, their role in cardiovascular risk reduction in diabetes may be especially important. |
 | | Evidence from the Helsinki Heart Study [14], which tested long-term fibrate (gemfibrozil) use in hypercholesterolaemic men and women without prior coronary disease, showed a significant reduction in coronary events, with the reduction among the small numbers of people with diabetes not being separately significant, but appearing somewhat greater [15]. |
| www.cardiab.com /content/3/1/9 (4839 words) |